McGuire B W, Sia L L, Leese P T, Gutierrez M L, Stokstad E L
Clinical Research Department, Alpha Therapeutic Corporation, Los Angeles, CA.
Clin Pharm. 1988 Jan;7(1):52-8.
The pharmacokinetics of leucovorin was evaluated after intravenous, intramuscular, and oral administration in a randomized crossover study of 37 healthy men. A single 25-mg dose of leucovorin calcium was administered intravenously, intramuscularly, or orally to the subjects. Blood samples were obtained immediately before and at 13 time points up to 24 hours after the leucovorin dose. The three treatment phases were separated by one-week intervals. Bioavailability was assessed by measuring over 24 hours the blood concentrations of total folates, the parent compound 5-formyltetrahydrofolate, and the metabolite 5-methyltetrahydrofolate, using differential microbiologic assays with Lactobacillus casei and Streptococcus faecalis. Both intravenous and intramuscular administration produced rapid increases in serum concentrations of biologically active folates; these rises were sustained over time and were still detectable at 24 hours after drug administration. The bioavailability of intravenous and intramuscular doses was comparable based on area under the serum concentration-time curve, although for intramuscular administration, the peak concentration was lower and the time to peak concentration was longer. The initial rise in serum folate with intravenous and intramuscular dosing represented 5-formyltetrahydrofolate; this fell concomitantly with the appearance of 5-methyltetrahydrofolate. Oral leucovorin was 92% bioavailable compared with intravenous administration and produced a predictably different pattern of circulating folates, 5-methyltetrahydrofolate being the predominant form. Terminal elimination half-life, apparent volume of distribution, and clearance of total folate were not significantly different among the three treatments.(ABSTRACT TRUNCATED AT 250 WORDS)
在一项针对37名健康男性的随机交叉研究中,评估了亚叶酸钙静脉注射、肌肉注射和口服给药后的药代动力学。向受试者静脉注射、肌肉注射或口服单剂量25毫克的亚叶酸钙。在亚叶酸钙给药前及给药后24小时内的13个时间点采集血样。三个治疗阶段间隔一周。通过使用干酪乳杆菌和粪肠球菌的差异微生物学测定法,在24小时内测量总叶酸、母体化合物5-甲酰四氢叶酸和代谢物5-甲基四氢叶酸的血药浓度,评估生物利用度。静脉注射和肌肉注射均使具有生物活性的叶酸血清浓度迅速升高;这些升高随时间持续,给药后24小时仍可检测到。基于血清浓度-时间曲线下面积,静脉注射和肌肉注射剂量的生物利用度相当,尽管肌肉注射时,峰值浓度较低,达峰时间较长。静脉注射和肌肉注射给药后血清叶酸的初始升高代表5-甲酰四氢叶酸;其下降与5-甲基四氢叶酸的出现同时发生。与静脉注射相比,口服亚叶酸钙的生物利用度为92%,并产生了可预测的不同循环叶酸模式,5-甲基四氢叶酸为主要形式。三种治疗方法之间,总叶酸的终末消除半衰期、表观分布容积和清除率无显著差异。(摘要截短至250字)